Magnus Essand – Immunotherapy of Cancer

Immunotherapy of cancer has emerged as one of the most promising new developments in medicine. The research of Magnus Essand's group mainly concerns translational cancer immunotherapy, focusing on oncolytic cancer-killing viruses and CAR T-cells. The work is mostly preclinical and based on studies on patient samples and advanced mouse models but two oncolytic viruses developed in the lab are now being evaluated in clinical trials for neuroendocrine cancer and prostate cancer. A current preclinical focus is to develop neurotropic viruses for treatment of glioblastoma, the most aggressive form of brain cancer.